Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PROCEPT BioRobotics (PRCT) EBT (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed EBT for 6 consecutive years, with -$29.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 60.4% to -$29.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$95.4 million, a 4.76% decrease, with the full-year FY2025 number at -$95.4 million, down 4.76% from a year prior.
  • EBT was -$29.7 million for Q4 2025 at PROCEPT BioRobotics, down from -$21.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$12.8 million in Q1 2021 to a low of -$29.7 million in Q4 2025.
  • A 5-year average of -$21.8 million and a median of -$22.0 million in 2022 define the central range for EBT.
  • Peak YoY movement for EBT: crashed 65.75% in 2023, then skyrocketed 32.58% in 2024.
  • PROCEPT BioRobotics' EBT stood at -$18.3 million in 2021, then crashed by 35.79% to -$24.9 million in 2022, then fell by 10.07% to -$27.4 million in 2023, then surged by 32.58% to -$18.5 million in 2024, then tumbled by 60.4% to -$29.7 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's EBT are -$29.7 million (Q4 2025), -$21.4 million (Q3 2025), and -$19.6 million (Q2 2025).